Industry veteran Dr Steen Klysner appointed as Amarna's new CEO

Amarna Therapeutics has announced the appointment of a new Chief Executive Officer (CEO), hiring industry veteran Dr Steen Klysner to the role.

Bringing over 30 years of industry experience to his new role, Dr Klysner has served as Senior Vice President (SVP) of preclinical R&D and SVP of Quality of Merck KGaA’s Allergy Business Unit Allergopharma and CEO of Nordic Vaccine, as well as holding roles at Pharmexa and Novo Nordisk. He joins Amarna from his most recent role as CEO of the Swedish ExpreS2ion Biotech Holding AB and the Danish ExpreS2ion Biotechnologies ApS.

Alongside this news, Amarna also announced that current CEO and Founder Ben van Leent has been appointed to the company’s Supervisory Board. Van Leent commented on Dr Klysner’s appointment: “I have full confidence that Steen, a very passionate and talented leader, will provide the leadership and expertise needed to guide Amarna through the next phases of growth. I look forward to working with Steen to drive forward Amarna’s product candidates.”

The Chairman of Amarna’s Supervisory Board, Thomas Eldered, also remarked: “I am very pleased to welcome Steen Klysner as our new CEO. Steen brings an extensive background as a biotech CEO to Swedish ExpreS2ion Biotech Holding AB & the Danish ExpreS2ion Biotechnologies ApS, preceded by an impressive track record in execution and value creation within the biotech industry. His leadership experience makes Steen an ideal candidate to lead Amarna into its next stage of growth and development. We are extremely grateful for Ben van Leent’s leadership and contributions to Amarna as both founder and CEO, and we are excited about the opportunity to focus his outstanding expertise as member of our Board.”